Akoya Biosciences is a medical instruments & supplies business based in the US. Akoya Biosciences shares (AKYA) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.50 – a decrease of 2.6% over the previous week. Akoya Biosciences employs 330 staff and has a trailing 12-month revenue of around $86.8 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $1.50 |
|---|---|
| 52-week range | $1.43 - $5.16 |
| 50-day moving average | $2.33 |
| 200-day moving average | $2.46 |
| Wall St. target price | $3.48 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.16 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.5 from 2025-03-14
| 1 week (2025-03-07) | -5.66% |
|---|---|
| 1 month (2025-02-14) | -35.06% |
| 3 months (2024-12-17) | -40.94% |
| 6 months (2024-09-17) | -47.92% |
| 1 year (2024-03-15) | -69.45% |
|---|---|
| 2 years (2023-03-16) | -81.41% |
| 3 years (2022-03-16) | 12.79 |
| 5 years (2020-03-13) | N/A |
| Revenue TTM | $86.8 million |
|---|---|
| Gross profit TTM | $50.1 million |
| Return on assets TTM | -18.02% |
| Return on equity TTM | -153.34% |
| Profit margin | -66.77% |
| Book value | $0.28 |
| Market Capitalization | $74.4 million |
TTM: trailing 12 months
We're not expecting Akoya Biosciences to pay a dividend over the next 12 months.
You may also wish to consider:
Over the last 12 months, Akoya Biosciences's shares have ranged in value from as little as $1.43 up to $5.1625. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Akoya Biosciences's is 1.322. This would suggest that Akoya Biosciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
To put Akoya Biosciences's beta into context you can compare it against those of similar companies.
Akoya Biosciences, Inc. , a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. It has a collaboration agreement with NeraCare that enables personalized therapy selection for early-stage melanoma patients; and license agreement with NeraCare for the development and commercialization of the immunoprint test for early-stage melanoma patient treatment decisions. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.
Our picks of the best brokerage accounts for index funds for beginners, teens, proprietary funds and more.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
Check out the best-performing ETFs so far in 2025.